CA2863578C - Methods and compositions for increasing sialic acid production and treating sialic related disease conditions - Google Patents

Methods and compositions for increasing sialic acid production and treating sialic related disease conditions Download PDF

Info

Publication number
CA2863578C
CA2863578C CA2863578A CA2863578A CA2863578C CA 2863578 C CA2863578 C CA 2863578C CA 2863578 A CA2863578 A CA 2863578A CA 2863578 A CA2863578 A CA 2863578A CA 2863578 C CA2863578 C CA 2863578C
Authority
CA
Canada
Prior art keywords
methods
gne
peptide
cell
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2863578A
Other languages
English (en)
French (fr)
Other versions
CA2863578A1 (en
Inventor
Daniel Darvish
Yadira Valles-Ayoub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HIBM Research Group Inc
Original Assignee
HIBM Research Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HIBM Research Group Inc filed Critical HIBM Research Group Inc
Publication of CA2863578A1 publication Critical patent/CA2863578A1/en
Application granted granted Critical
Publication of CA2863578C publication Critical patent/CA2863578C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
    • A61M5/425—Protruding skin to facilitate piercing, e.g. vacuum cylinders, vein immobilising means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2863578A 2011-02-01 2012-02-01 Methods and compositions for increasing sialic acid production and treating sialic related disease conditions Active CA2863578C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438585P 2011-02-01 2011-02-01
US61/438,585 2011-02-01
PCT/US2012/023536 WO2012106465A2 (en) 2011-02-01 2012-02-01 Methods and compositions for increasing sialic acid production and treating sialic related disease conditions

Publications (2)

Publication Number Publication Date
CA2863578A1 CA2863578A1 (en) 2012-08-09
CA2863578C true CA2863578C (en) 2021-10-26

Family

ID=46603295

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2863578A Active CA2863578C (en) 2011-02-01 2012-02-01 Methods and compositions for increasing sialic acid production and treating sialic related disease conditions

Country Status (9)

Country Link
US (2) US20130030040A1 (enExample)
EP (2) EP3202425A1 (enExample)
JP (2) JP2014506787A (enExample)
KR (2) KR102257741B1 (enExample)
AU (2) AU2012212162A1 (enExample)
CA (1) CA2863578C (enExample)
IL (1) IL227773B (enExample)
MX (1) MX365095B (enExample)
WO (1) WO2012106465A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140057856A1 (en) * 2012-08-22 2014-02-27 The Regents Of The Universtiy Of California Compositions and Methods For Enhancing Sialic Acid Levels In Tissue
US20150322439A1 (en) * 2012-11-19 2015-11-12 Nature Technology Corporation Replicative minicircle vectors with improved expression
US20140256639A1 (en) * 2013-02-14 2014-09-11 The Regents Of The University Of California Peptoid neutralizing agents
CN103088090B (zh) * 2013-03-01 2014-06-04 南京工业大学 一种n-乙酰葡萄糖胺异构酶在生产n-乙酰甘露糖胺中的应用
CA2967595A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN116217729A (zh) 2015-11-12 2023-06-06 思进公司 聚糖相互作用化合物及使用方法
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
CN110913903B (zh) 2017-03-03 2024-03-01 思进股份有限公司 聚糖相互作用化合物和使用方法
CN108285886A (zh) * 2018-01-30 2018-07-17 江南大学 重组枯草芽孢杆菌全细胞转化生产n-乙酰神经氨酸的方法
US11865165B2 (en) 2018-09-18 2024-01-09 Daniel DARVISH GNE as a therapeutic agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173465A9 (en) 1995-10-11 2007-07-26 Monahan Sean D Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
AU2001236739A1 (en) * 2000-02-08 2001-08-20 Genentech Inc. Improved sialylation of glycoproteins
WO2004071177A2 (en) * 2003-02-11 2004-08-26 Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University Sialylation of glycoproteins in plants
WO2005030292A2 (en) * 2003-09-26 2005-04-07 The Trustees Of The University Of Pennsylvania Methods, compositions and apparatus for delivering heterologous molecules to cells
WO2008001023A1 (en) 2006-06-27 2008-01-03 Gigabeam Corporation Cellular communication system
JP5415283B2 (ja) * 2007-02-07 2014-02-12 グラダリス インク． シアル酸産生を調節し、遺伝性封入体ミオパチーを治療する方法及び組成物
CA2684534C (en) 2007-04-17 2017-04-04 National Research Council Of Canada Constructs for enhancement of gene expression in muscle
US9018174B2 (en) * 2008-05-28 2015-04-28 Hibm Research Group, Inc. Mouse model and treatment of hereditary inclusion body myopathy
AU2009291861A1 (en) 2008-09-09 2010-03-18 The Regents Of The University Of California Elimination of a contaminating non-human sialic acid by metabolic competition
US9045759B2 (en) * 2009-01-21 2015-06-02 James Arthur Williams DNA plasmids with improved copy number
CN102482674B (zh) * 2010-02-08 2014-03-26 韩国科学技术院 制备具有高唾液酸含量的重组糖蛋白的方法

Also Published As

Publication number Publication date
MX2013008948A (es) 2014-02-18
WO2012106465A3 (en) 2014-04-24
KR20140034150A (ko) 2014-03-19
EP3202425A1 (en) 2017-08-09
JP2014506787A (ja) 2014-03-20
WO2012106465A2 (en) 2012-08-09
AU2017203027B2 (en) 2019-08-15
AU2017203027A1 (en) 2017-07-20
KR102257741B1 (ko) 2021-05-28
JP2017158577A (ja) 2017-09-14
AU2012212162A1 (en) 2013-08-29
IL227773A0 (en) 2013-09-30
EP2670442A4 (en) 2015-07-29
MX365095B (es) 2019-05-22
IL227773B (en) 2021-03-25
EP2670442A2 (en) 2013-12-11
KR20190108178A (ko) 2019-09-23
US20140275230A1 (en) 2014-09-18
CA2863578A1 (en) 2012-08-09
US20130030040A1 (en) 2013-01-31
US10098969B2 (en) 2018-10-16

Similar Documents

Publication Publication Date Title
CA2863578C (en) Methods and compositions for increasing sialic acid production and treating sialic related disease conditions
MY160897A (en) Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof
MX2011011215A (es) Polipeptido que degrada carbohidratos y usos del mismo.
MY187542A (en) Carbohydrate degrading polypeptide and uses thereof
IN2012DN01652A (enExample)
IN2014CN01706A (enExample)
WO2013027999A3 (ko) 열 안정성이 향상된 사이코스 에피머화 효소 변이체 및 이를 이용한 사이코스의 연속적 생산
MX2010009465A (es) Una celula fermentadora de azucar pentosa.
EA201300054A1 (ru) Полипептид, обладающий активностью бета-глюкозидазы, и его применение
HK1198170A1 (en) Pseudomonas exotoxin a with less immunogenic b cell epitopes
NZ595497A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
NZ596660A (en) Dig-5 insecticidal cry toxins
MX2011009009A (es) Enzimas de celulosa resistentes a lignina.
NZ742660A (en) Variants of chymosin with improved milk-clotting properties
MX2010009809A (es) Una celula fermentadora de azucar pentosa.
MY159074A (en) Polypeptide having d-lactate dehydrogenase activity, polynucleotide encoding the polypeptide, and process for production of d-lactic acid
MY185050A (en) A pentose sugar fermenting cell
EA201300057A1 (ru) Полипептид, обладающий углеводдеградирующей активностью, и его применения
WO2013093029A3 (en) Variants of yeast ndi1 gene, and uses thereof in the treatment of disease associated with mitochondrial dysfunction
MY170467A (en) High molecular weight pha-producing microbe and method of producing high molecular weight pha using same
EA201300059A1 (ru) Полипептид, обладающий активностью сволленина, и его применение
WO2013052814A8 (en) E1 enzyme mutants and uses thereof
WO2011159092A3 (ko) 신규 토양 미생물과 상기 토양 미생물로부터 분리된 신규한 산화환원효소, 상기 산화환원 효소를 암호화하는 유전자 및 이들을 이용한 비당체의 생산방법
IN2015DN02044A (enExample)
MY155616A (en) Fermentation of moderately thermophilic bacilli on sucrose

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170126